echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JAMA: Who is stronger with GLP-1 receptor agonists for weight control?

    JAMA: Who is stronger with GLP-1 receptor agonists for weight control?

    • Last Update: 2022-01-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The STEP study confirmed that weekly 2.
    4 mg of the GLP-1 receptor agonist semaglutide was effective in reducing body weight in obese people, regardless of whether they had
    diabetes
    .
    Semaglutide is the second GLP-1 receptor agonist approved for weight management, the first being liraglutide

    .
    We investigated the difference in efficacy and adverse events of semaglutide 2.
    4 mg subcutaneously once weekly or liraglutide 3.
    0 mg subcutaneously once daily in overweight or obese people

    .

    Diabetes : We investigated the difference in efficacy and adverse events between weekly subcutaneous 2.
    4 mg semaglutide or 3.
    0 mg daily subcutaneous liraglutide in overweight or obese people

    .
    We investigated the difference in efficacy and adverse events of semaglutide 2.
    4 mg subcutaneously once weekly or liraglutide 3.
    0 mg subcutaneously once daily in overweight or obese people

    .


    This study was conducted in 19 clinical centers in the United States and was followed up until May 2021.
    It is a randomized, open, 68-week phase 3b trial with a BMI of 30 or more or 27 and 1 or more weight-related Patients with comorbidities but no diabetes participated in the study.
    On the basis of diet and exercise, patients were randomized to receive 2.
    4 mg of semaglutide once a week (n=126) and 3.
    0 mg of liraglutide once a day ( n=127) or placebo (n=85)

    .
    The primary endpoint of the study was weight change at 68 weeks

    .

    The mean patient age was 49 years, 265 women, mean weight 104.
    5 kg, mean body mass index 37.
    5, 319 (94.
    4%) completed the trial and 271 (80.
    2%) completed the treatment

    .
    The mean weight change from baseline was -15.
    8% in the semaglutide group, -6.
    4% in the liraglutide group, and -1.
    9% in the placebo group

    .
    Compared with liraglutide, participants in the semaglutide group had an advantage in weight loss of 10% or more, 15% or more, and 20% or more, respectively, 70.
    9% vs 25.
    6% (OR=6.
    3) , 55.
    6% vs 12.
    0% (OR=7.
    9), 38.
    5% vs 6.
    0% (OR=8.
    2)

    .
    The discontinuation rate for any reason was 13.
    5% in the semaglutide group and 27.
    6% in the liraglutide group

    .
    The reported rate of gastrointestinal adverse events was 84.
    1% in the semaglutide group and 82.
    7% in the liraglutide group

    .



    The mean weight change from baseline was -15.
    8% in the semaglutide group, -6.
    4% in the liraglutide group, and -1.
    9% in the placebo group

    .
    The mean weight change from baseline was -15.
    8% in the semaglutide group, -6.
    4% in the liraglutide group, and -1.
    9% in the placebo group

    .

    Weight control effect of semaglutide vs liraglutide

    Weight Control Effects of Semaglutide vs Liraglutide Weight Control Effects of Semaglutide vs Liraglutide

    The study concluded that in obese or overweight non-diabetic patients, once-weekly semaglutide was more effective than once-daily liraglutide for weight loss
    .

    Original Source:
    Domenica M.
    Rubino et al.
    Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial.
    JAMA , January 11, 2022
    .

    In obese or overweight non-diabetic patients, once-weekly semaglutide was superior to once-daily liraglutide for weight loss
    .
    In obese or overweight non-diabetic patients, once-weekly semaglutide was superior to once-daily liraglutide for weight loss
    .

    Original Source:
    Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial.
    JAMA LEAVES

    THIS
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.